Its good and it fills a gap nicely in the schedule and we are now in-clinic, and around the corner from Phase 2 trials with this new addition.
When Cantrixil enters in the next month or so we have two drugs in trials one in phase 1 and one about to go to phase 2.... and with IND + one starting late next year.
They have molecule for phase 2 trials and after phase two we enter into partnership on phase three trials with a big brother it seems a good decision - we could be in funded phase 3 with 'something' within two years.
It also opens the doors for Cantrixil looking for a partner for phase three which must still be a good two years of.
It shortens the time to potential revenue.
If so it proves Novogen can now handle a relationship and the progression to revenue streams - meaning self funded... its a new Novogen.
I like it though haven't read through properly.
Its good and it fills a gap nicely in the schedule and we are...
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)